Vaccine development is evolving with platform technologies, rapid manufacturing, and global collaboration to enhance preparedness and public trust.
2
Adaptable platforms like mRNA and viral vectors enable rapid response to emerging pathogens while ensuring scalability and manufacturability.
3
The COVID-19 pandemic highlighted supply chain vulnerabilities, prompting CDMOs to adopt dual-sourcing strategies and improve inventory planning.
4
Public trust in vaccines relies on transparent communication and scientific literacy to counter misinformation and enhance confidence in public health.
5
International collaboration in vaccine development is built on trust, fostering partnerships between biotech firms, public institutions, and governments.
